Medicare AdvantagePrior AuthMedium impact
Sancuso® (granisetron) transdermal patch (Revised)
Humana·Oncology, Palliative Care·Medicare Advantage
We identified it
Jul 2, 2026
Summary
This is a revised Prior Authorization policy for Sancuso® (granisetron) transdermal patch affecting Medicare Advantage members. The policy requires prior authorization before dispensing this anti-nausea medication. Billing teams must implement prior auth requirements in their systems immediately.
Action Required
Immediately: Billing team must update prior authorization system to require approval before dispensing Sancuso® (granisetron) transdermal patch (J8501) for all Medicare Advantage members. Add prior auth requirement to pharmacy billing software and alert pharmacy staff to obtain authorization before claim submission. Flag all J8501 claims without documented prior authorization for denial. Reference the complete policy at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a56a5ec for specific approval criteria and any clinical documentation requirements.